M. Elaine Husni, MD, MPH

Appointed
2005

Education & Fellowships

Fellowship - Brigham & Women's Hospital
Rheumatology
Boston, MA USA
2003

Residency - Beth Israel Deaconess Medical Center and Harvard Medical School
Internal Medicine
Boston, MA USA
1999

Internship - Beth Israel Deaconess Medical Center and Harvard Medical School
Internal Medicine
Boston, MA USA
1997

Medical Education - Boston University School of Medicine
Boston, MA USA
1996

Graduate School - Boston University School of Medicine
Boston, MA USA
1995

Undergraduate - Boston College
Psychology
Chestnut Hill, MA USA
1990

Additional Training

• Masters in Public Health with a concentration in health outcomes research/health services research

Professional Highlights

• Director, Arthritis and Musculoskeletal Treatment Center
• Director, Clinical Outcomes Research

Certifications

• Internal Medicine - Rheumatology

Specialty Interests

Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Joint pain, use of complementary and alternative medicine for arthritis and health outcomes research

Awards & Honors

• Physician Scientist Development Award
• Clinical Investigator Award
• Faculty award for excellence in tearching-Brigham and Women's Hospital, Harvard Medical School

Memberships

• American College of Rheumatology

See publications for M. Elaine Husni, MD, MPH.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 7/3/2022, Dr. Husni has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Husni receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Novartis Pharmaceuticals Corporation

Donation of Financial Interest. Dr. Husni has consulted for, received compensation for serving as a fiduciary from, or received royalties from the following companies but instructed them to donate all compensation to not-for-profit causes or to the Cleveland Clinic to support research and education:

• UCB Pharmaceuticals, Inc.
• Regeneron Pharmaceuticals, Inc.
• AbbVie, Inc.
• Bristol-Myers Squibb
• Novartis Pharmaceuticals Corporation

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.